Breathe Well Live Well
|
Rigel says Pfizer returns asthma therapy rights
Reuters May 6 (Reuters) – Rigel Pharmaceuticals Inc said Pfizer Inc has returned the rights to Rigel's inhaled asthma therapy, following the world's biggest drugmaker's decision to exit research and development in the allergy and respiratory therapeutic area. … Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer Hands Back Rigel Drug |
View full post on asthma – Google News
|
Rigel Assumes Development Responsibility for Inhaled Asthma Therapy
PR Newswire (press release) SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 … |
View full post on asthma – Google News
|
Add-on Therapy Improves Outcomes in Severe Asthma
Medscape May 5, 2011 — Omalizumab may provide additional relief for patients with severe allergic asthma who do not respond adequately to inhaled corticosteroids (ICS) or long-acting beta 2 -agonists (LABAs), investigators report in the May 3 issue of the … |
View full post on asthma – Google News
 FRANCE 24 |
Anti-Leukotrienes as Good as Standard Asthma Therapy
MedPage Today Note that these studies found that the real-world effectiveness of a leukotriene-receptor antagonist was effective for first-line asthma-controller therapy or as add-on therapy in patients already … Asthma pill as effective as inhalers and easier to use Asthma Pills Work as Well as Inhaled Steroids: Study Pills better for treating asthma than inhalers |
View full post on asthma – Google News
|
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for …
PR Newswire (press release) Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. … |
View full post on asthma – Google News
|
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for …
SYS-CON Media (press release) Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. … |
View full post on asthma – Google News
|
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a …
7thSpace Interactive (press release) There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. … |
View full post on asthma – Google News
|
School-Based Asthma Therapy Intervention Improves Symptoms
Medscape March 9, 2011 — A School-Based Asthma Therapy intervention significantly improves symptoms in urban children with persistent asthma, according to the results of a randomized controlled trial reported in the March issue of the Archives of Pediatrics … School-based intervention improved asthma symptoms |
View full post on asthma – Google News
|
Rescue Therapy for Asthma May Help Avoid Daily Use of Corticosteroids
Medscape "Daily inhaled corticosteroids are an effective treatment for mild persistent asthma, but some children have exacerbations even with good day-to-day control, and many discontinue treatment after becoming asymptomatic," write Fernando D. Martinez, MD, … |
View full post on asthma – Google News
|
Asthma rescue therapy avoids growth retardation in children
Nursing Times They suggest use of rescue inhaled corticosteroid could be an effective step-down alternative to discontinuation of such treatment after asthma control is achieved. We're going viral! Have you friends heard about the 'seat on the board' petition? … |
View full post on asthma – Google News